Impedimed (ASX:IPD) share price rises with 46% lift in revenues

Let’s take a closer look.
The post Impedimed (ASX:IPD) share price rises with 46% lift in revenues appeared first on The Motley Fool Australia. –

The Impedimed Limited (ASX: IPD) share price is appreciating after the company released its full-year results for FY21.

At the time of writing, shares in the healthcare company are trading for 13 cents each – up 4%. For context, the ASX All Ordinaries Index (ASX: XAO) is 0.25% higher.

Let’s take a closer look at today’s announcement.

Impedimed share price lifts with reduction in losses

Revenue of $8.4 million – up 46.5% on the prior corresponding period (pcp). This includes a 64% growth in revenue from its SOZO software, which totalled $7.6 million.
Loss from ordinary activities of $20.7 million, which is down 3% on the pcp.
Net operating cash outflows for the period of $13.3 million. This is down from the $19.2 million outflow in the pcp.
Nil dividend paid for the year, which is the same as FY20.

What happened in FY21 for Impedimed?

The Impedimed share price rocketed 13% in November when AstraZeneca plc (LSE: AZN) announced it was using SOZO for phase II clinical trials. The product was used for measuring fluid volumes in patients with chronic kidney disease.

Besides SOZO, Impedimed also announced news in relation to its ‘Prevent’ treatment and ‘HF-Dex’ system.

What did management say?

Impedimed CEO and Managing Director, Richard Carreon, said

Our transition to a connected digital health platform put the Company in a strong position to thrive during a very turbulent year. We have built a strong and resilient business, with quarter-over-quarter record results. Throughout the past year, our Company continued to prove its resilience, as we signed SOZO contracts in excess of $12.0 million, had a churn rate of just 1%, and a contract renewal rate of 100% throughout the entire financial year.

What’s next for Impedimed?

Just in the last 2 days, Impedimed released 2 statements that were material to the Impedimed share price.

The first relates to designation of a product in the US and the second on an R&D tax rebate.

On the first matter, SOZO received “Breakthrough Device Designation” from the US Food and Drug Administration (FDA) for use in renal patients. The product will be used to measure fluids in patients undergoing dialysis. The company says the designation is the “perfect forum” to ultimately get FDA clearance.

On the second, the company received a $1.8 million research and development (R&D) from the Australian government. Last year the company received a $2.6 million refund.

Impedimed share price snapshot

Over the past 12 months, the Impedimed share price has increased 62.5%. Year-to-date, however, it is only up 8.33%. This is below the All Ords Index. Impedimed has a market capitalisation of about $187 million.

The post Impedimed (ASX:IPD) share price rises with 46% lift in revenues appeared first on The Motley Fool Australia.

Should you invest $1,000 in Impedimed right now?

Before you consider Impedimed, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Impedimed wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Why Bravura, Nine, Reece, & Zip shares are sinking today

Why the Althea (ASX:AGH) share price is sinking 10% today
How did the Polynovo (ASX:PNV) share price respond last earnings season?
The Appen (ASX:APX) share price slumped 7% last time it reported
Qantas (ASX:QAN) share price lifts 5% as ad campaign hits home

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!